AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24275629 — intervention group
Group type: EXPERIMENTAL
Intervention: RHI added to FRS, BNP, and SYNTAXsc
Number of subjects: 528
Study 24275632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 9974
Study 24275632 — intervention group
Group type: COMPARATOR
Intervention: Patient education
Number of subjects: 9974
Study 24275632 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug use
Number of subjects: 9974
Study 24275804 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured questionnaire identifying renal dysfunction risk factors (renal disease, renal surgery, hypertension, gout, diabetes)
Number of subjects: 1467
Study 24275804 — intervention group
Group type: COMPARATOR
Intervention: No risk factors reported
Number of subjects: 1467
Study 24275804 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire for patients <70 years old and eGFR determination for patients >70 years old
Number of subjects: 1467
Study 24275804 — intervention group
Group type: EXPERIMENTAL
Intervention: General population referred for CT/MRI
Number of subjects: 1467
Study 24276017 — intervention group
Group type: COMPARATOR
Intervention: Loss-of-function (LOF) MC4R variants
Number of subjects: 217
Study 24276017 — intervention group
Group type: COMPARATOR
Intervention: Gain-of-function (GOF) MC4R variants
Number of subjects: 217
Study 24276017 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF SNPs rs12291186 and rs6265
Number of subjects: 217
Study 24276017 — intervention group
Group type: COMPARATOR
Intervention: Loss-of-function (LOF) MC4R variants in Hispanic cohort
Number of subjects: 217
Study 24276047 — intervention group
Group type: EXPERIMENTAL
Intervention: EZN-3042 2.5 mg/kg/dose administered as a single agent on days -5 and -2, then in combination with a 4-drug reinduction chemotherapy on days 8, 15, 22, and 29.
Number of subjects: 6
Study 24276047 — intervention group
Group type: EXPERIMENTAL
Intervention: EZN-3042 2.5 mg/kg/dose (single agent)
Number of subjects: 6
Study 24276047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EZN-3042 with intensive reinduction chemotherapy
Number of subjects: 6
Study 24277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (single-agent course following induction)
Number of subjects: 266
Study 24277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (added to the second phase of induction)
Number of subjects: 266
Study 24277073 — intervention group
Group type: COMPARATOR
Intervention: Pre-imatinib standard treatment
Number of subjects: 266
Study 24277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 266
Study 24277679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplatelet (IP) serotonin (5-HT) levels before surgery
Number of subjects: 60
Study 24277679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplatelet (IP) serotonin (5-HT) levels
Number of subjects: 60
Study 24278393 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise test
Number of subjects: 12
Study 24278393 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 week supervised training period (walking/running 4 times per week at 60% heart rate reserve)
Number of subjects: 12
Study 24278400 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg)
Number of subjects: 59
Study 24279643 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate autonomic dysregulation (3<BRS≤6)
Number of subjects: 916
Study 24279643 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe autonomic dysregulation (BRS≤3)
Number of subjects: 916
Study 24279643 — intervention group
Group type: COMPARATOR
Intervention: Normal BRS (>6)
Number of subjects: 916
Study 24280543 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obstructive chronic bronchitis (NCB)
Number of subjects: 597
Study 24281137 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective A1 Adenosine Receptor Antagonist Rolofylline
Number of subjects: 1962
Study 24281137 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blood urea nitrogen >35 mg/dL and increase in creatinine >0.1 mg/dL per day
Number of subjects: 1962
Study 24281137 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable or decreasing creatinine
Number of subjects: 1962
Study 24281137 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1962
Study 24281330 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 8583
Study 24282221 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPD score assessment using an automated pupillometer
Number of subjects: 103
Study 24282221 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 103
Study 24282221 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 103
Study 24282221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined structure function index (CSFI)
Number of subjects: 103
Study 24282221 — intervention group
Group type: COMPARATOR
Intervention: RAPD score > 0.3
Number of subjects: 103
Study 24282247 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise programme (26 weeks)
Number of subjects: 97
Study 24282248 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole and berberine
Number of subjects: 660
Study 24282248 — intervention group
Group type: COMPARATOR
Intervention: letrozole and berberine placebo
Number of subjects: 660
Study 24282248 — intervention group
Group type: COMPARATOR
Intervention: letrozole placebo and berberine
Number of subjects: 660
Study 24282249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation programme plus usual care
Number of subjects: 154
Study 24282249 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 154
Study 24282316 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by steps per day and time spent in vigorous physical activity)
Number of subjects: 95
Study 24282316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 95
Study 24282316 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 95
Study 24283202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID, with potential increase to 10 mg BID
Number of subjects: 0
Study 24283202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID
Number of subjects: 0
Study 24283216 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 genotype (rs18000497 T-alleles)
Number of subjects: 451
Study 24283216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (OBELDICKS)
Number of subjects: 451
Study 24283216 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional comparison with lean adult controls
Number of subjects: 451
Study 24284293 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEAR regimen (Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin)
Number of subjects: 15
Study 24284413 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccination (0 and 6 to 12 months)
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with anti-TNF monoclonal antibody infliximab or adalimumab
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination in patients not treated with anti-TNF agents
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with ≥2 immunosuppressants
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with <2 immunosuppressants
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination comparing anti-TNF alone with anti-TNF and other immunosuppressants
Number of subjects: 419
Study 24284413 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccination in patients receiving anti-TNF therapy
Number of subjects: 419
Study 24284865 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzee adenovirus-MVA immunisation
Number of subjects: 14
Study 24284925 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24285015 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCl liposome injection (DLI) 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by Bexarotene 300 mg/m(2) orally for 16 weeks
Number of subjects: 37
Study 24285015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene 300 mg/m(2) orally for 16 weeks
Number of subjects: 37
Study 24285681 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF) estradiol levels in AAW
Number of subjects: 29
Study 24285681 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF) estrone levels in AAW
Number of subjects: 29
Study 24285681 — intervention group
Group type: EXPERIMENTAL
Intervention: FF androstenedione to estrone ratio in AAW
Number of subjects: 29
Study 24285681 — intervention group
Group type: EXPERIMENTAL
Intervention: FF testosterone to estradiol ratio in AAW
Number of subjects: 29
Study 24285681 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulosa cell aromatase mRNA expression in AAW
Number of subjects: 29
Study 24285681 — intervention group
Group type: COMPARATOR
Intervention: FSH, inhibin A, inhibin B, and AMH levels
Number of subjects: 29
Study 24286269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 88
Study 24286269 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 88
Study 24286269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 88
Study 24287082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mononuclear Cells (BMMC) infusion
Number of subjects: 0
Study 24287594 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 400
Study 24287594 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exposed to CBZ)
Number of subjects: 400
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral warts
Number of subjects: 70
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related skin disorders
Number of subjects: 70
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-malignant and malignant skin disorders
Number of subjects: 70
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial and fungal infections
Number of subjects: 70
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidences of skin disorders
Number of subjects: 70
Study 24287733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence data of skin disorders
Number of subjects: 70
Study 24288021 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network size and type, perceived emotional support
Number of subjects: 150
Study 24288021 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental support seeking
Number of subjects: 150
Study 24288021 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental support seeking with interdependent self-construal
Number of subjects: 150
Study 24288021 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 150
Study 24288021 — intervention group
Group type: EXPERIMENTAL
Intervention: Less interdependent self-construal with more instrumental support
Number of subjects: 150
Study 24288556 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 150
Study 24288556 — intervention group
Group type: COMPARATOR
Intervention: Standardized acupuncture
Number of subjects: 150
Study 24289141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paliperidone extended-release (ER) 3 to 12 mg daily for 26 to 52 weeks
Number of subjects: 213
Study 24289658 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV/10 (seasonal trivalent inactivated vaccine 2010)
Number of subjects: 60
Study 24289658 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine
Number of subjects: 60
Study 24289796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration during labor
Number of subjects: 316
Study 24290461 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy with family-focused behavioral intervention
Number of subjects: 160
Study 24290615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter (SAD)
Number of subjects: 740
Study 24290615 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 740
Study 24290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 30
Study 24290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes (abnormal hemisphere)
Number of subjects: 30
Study 24290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes (normal hemisphere)
Number of subjects: 30
Study 24291224 — intervention group
Group type: EXPERIMENTAL
Intervention: GH stimulation testing with GHRH-arginine
Number of subjects: 138
Study 24291224 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak stimulated GH
Number of subjects: 138
Study 24291380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) therapy
Number of subjects: 35
Study 24291380 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 35
Study 24291783 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable everolimus-eluting vascular scaffold
Number of subjects: 101
Study 24292639 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 207
Study 24292639 — intervention group
Group type: COMPARATOR
Intervention: MetS+ individuals
Number of subjects: 207
Study 24292957 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 750 or 500 mg/day orally in 4-week cycles
Number of subjects: 80
Study 24293774 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot GnRHa (leuprolide 3.75-mg)
Number of subjects: 29
Study 24294924 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 ug/day
Number of subjects: 43
Study 24294924 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients
Number of subjects: 43
Study 24295096 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for depression in hospice caregivers, specific interventions not detailed.
Number of subjects: 0
Study 24295437 — intervention group
Group type: EXPERIMENTAL
Intervention: Histrelin implant (50-mg subcutaneous annually)
Number of subjects: 36
Study 24295572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (100 mg or 200 mg, twice a day) initiated 10 days before haemopoietic stem-cell transplantation until day 100, in combination with standard immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimus (0.03 mg/kg a day, titrated to a goal level of 8-12 ng/mL, starting day -3 until day 180)
Number of subjects: 50
Study 24295572 — intervention group
Group type: COMPARATOR
Intervention: Standard immunoprophylaxis of mycophenolate mofetil and tacrolimus
Number of subjects: 50
Study 24295986 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir-ritonavir (DNVr) plus peginterferon alfa-2a-ribavirin for 12 weeks
Number of subjects: 24
Study 24295986 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir-ritonavir (DNVr) plus peginterferon alfa-2a-ribavirin
Number of subjects: 24
Study 24296492 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel reduced-intensity conditioning (RIC) regimen consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan, and thiotepa followed by single umbilical cord blood transplantation (UCBT).
Number of subjects: 22
Study 24296713 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 34
Study 24296713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose stimulation
Number of subjects: 34
Study 24296713 — intervention group
Group type: COMPARATOR
Intervention: Control groups (severely obese normal glucose-tolerant and lean)
Number of subjects: 34
Study 24297161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 15
Study 24297771 — intervention group
Group type: EXPERIMENTAL
Intervention: Late PCI with optimal medical therapy (OMT)
Number of subjects: 43
Study 24297771 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 43
Study 24297771 — intervention group
Group type: EXPERIMENTAL
Intervention: Late PCI with OMT
Number of subjects: 43
Study 24297953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated (90)Y-ibritumomab tiuxetan (90Y-IT) administered in two doses of 11.1 MBq/kg, 8 to 12 weeks apart.
Number of subjects: 74
Study 24298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis administered within 90 minutes of ictus
Number of subjects: 0
Study 24298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis service
Number of subjects: 0
Study 24298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Future research
Number of subjects: 0
Study 24298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intra-arterial intervention such as thrombectomy
Number of subjects: 0
Study 24298851 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 24298851 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24300167 — intervention group
Group type: EXPERIMENTAL
Intervention: Q wave area
Number of subjects: 158
Study 24300167 — intervention group
Group type: EXPERIMENTAL
Intervention: Selvester QRS-score
Number of subjects: 158
Study 24300594 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23/PCV13 (n=50)
Number of subjects: 89
Study 24300594 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9/PCV13 (n=39)
Number of subjects: 89
Study 24300594 — intervention group
Group type: COMPARATOR
Intervention: PPV23/PCV13
Number of subjects: 89
Study 24300594 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9/PCV13
Number of subjects: 89
Study 24303954 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF biomarkers (MMP-8, MMP-9, Osteoprotegerin, C-reactive Protein, IL-1β)
Number of subjects: 100
Study 24303954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biofilm pathogens and GCF biomarkers with clinical measures
Number of subjects: 100
Study 24304125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitiligo
Number of subjects: 350
Study 24304654 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with invasive DBP and MBP
Number of subjects: 34
Study 24304654 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with oscillometric brachial SBP and DBP
Number of subjects: 34
Study 24304654 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with DBP and MBP (ff = 0.33)
Number of subjects: 34
Study 24304654 — intervention group
Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with DBP and MBP (ff = 0.40)
Number of subjects: 34
Study 24304654 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration with average of 3 brachial BPs
Number of subjects: 34
Study 24304924 — intervention group
Group type: EXPERIMENTAL
Intervention: Foods with added fiber (23 g/d)
Number of subjects: 15
Study 24305645 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 20
Study 24305645 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 20
Study 24305979 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of arthralgia/myalgia/carpal tunnel (AMC) symptoms
Number of subjects: 4798
Study 24305979 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of vasomotor symptoms
Number of subjects: 4798
Study 24307008 — intervention group
Group type: EXPERIMENTAL
Intervention: Young smokers
Number of subjects: 72
Study 24307008 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonsmokers
Number of subjects: 72
Study 24307220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 691
Study 24307220 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC)
Number of subjects: 691
Study 24307220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH) to Lanthanum carbonate (LC) conversion
Number of subjects: 691
Study 24307472 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey assessing constructs from theoretical frameworks including fear appeal theories
Number of subjects: 481
Study 24307695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput sequencing (HTS) of T cell receptors (TCRB)
Number of subjects: 10
Study 24307992 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated diagnostic test using NMR spectrum of urine samples
Number of subjects: 988
Study 24308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 0
Study 24308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 0
Study 24308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 24308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 24308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 0
Study 24308871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose ingestion in IBS-D patients with lactose intolerance (LI)
Number of subjects: 55
Study 24308871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose ingestion in IBS-D patients with LI
Number of subjects: 55
Study 24308871 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of abdominal symptoms after lactose ingestion
Number of subjects: 55
Study 24309189 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(Cr+Cys)
Number of subjects: 1441
Study 24309189 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(Cr)
Number of subjects: 1441
Study 24309189 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(Cys)
Number of subjects: 1441
Study 24309189 — intervention group
Group type: EXPERIMENTAL
Intervention: BP and hemoglobin A1c
Number of subjects: 1441
Study 24309199 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-source based data-sharing infrastructure
Number of subjects: 0
Study 24309956 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurement of IGFBP7
Number of subjects: 142